



# Non-Invasive Fetal Aneuploidy Testing

Last Revision/Review Date: March 18, 2020

P&P # C.6.17

## Policy

The Medical Management Department reviews referral requests for authorization of Non-Invasive Fetal Aneuploidy Testing.

This Medical Policy does not constitute medical advice. When deciding coverage, the enrollee's specific plan document must be referenced. The terms of an enrollee's plan document (Certificate of Coverage (COC) or Summary Plan Description (SPD)) may differ from this Medical Policy. In the event of a conflict, the enrollee's specific benefit plan document supersedes this Medical Policy. All reviewers must first identify enrollee eligibility, any federal or state regulatory requirements, and the plan benefit coverage prior to use of this Medical Policy. Other Policies and Coverage Determination Guidelines may apply. Quartz reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary.

## Procedure

### A. Documentation Required:

To facilitate the authorization process referral requests **must** include **ALL** the following:

1. Name of specific NIPT test being requested;
2. Evidence supporting increased risk of aneuploidy (e.g., ultrasound results, First trimester serum screening results or genetic history);
3. Documentation of singleton pregnancy;
4. Estimated due date (EDD) or gestational age at time of lab draw;
5. Date or date range for lab draw;
6. Clinical record of genetic counseling (by OB, family practice provider, or genetics counselor);
7. Maternal date of birth;
8. For donor egg pregnancies, the age of the donor.

### B. Criteria for Medical Necessity:

Non-invasive fetal aneuploidy testing of maternal blood is considered medically necessary for detection of trisomy 13, 18 or 21 when **ALL** the following are met:

1. A pregnancy is considered at high risk of fetal aneuploidy when **ANY** of the following are met:
  - a. Increased risk for aneuploidy as determined by findings on ultrasound or first serum screening results; **OR**
  - b. Maternal history of previous aneuploid pregnancy; **OR**
  - c. Advanced maternal age of 35 years or older at the estimated date of delivery; **OR**

- d. Parental (maternal or paternal) balanced Robertsonian translocation with increased risk for fetal trisomy 13 or trisomy 21.
2. Singleton pregnancy; **AND**
3. Gestational age  $\geq$  10 weeks; **AND**
4. Clear documentation of pre-screening genetic counseling that includes a discussion regarding the need for confirmatory invasive testing (CVS or amniocentesis) if non-invasive fetal aneuploidy testing is abnormal.

**Note:**

If assisted reproduction with donor eggs was used to achieve pregnancy, 1b, 1c, and 1d above refer to the age and history of the egg donor.

Preimplantation genetic screening for aneuploidy does not preclude aneuploidy testing during pregnancy.

**C. Indications Considered Experimental, Investigational or not Medically Necessary:**

1. Testing for all conditions other than the trisomies listed above.
2. Gender determination.
3. Expanded noninvasive prenatal testing panels that include additional testing for microdeletion/microduplication syndromes.
4. Use in multiple gestation pregnancy including co-twin demise and vanishing twin syndrome.

**HCPCS/CPT CODES:**

81420	Fetal chromosomal aneuploidy (e.g., trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21.
-------	--

**References:**

American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal Fetal Medicine. Practice Bulletin No.163. Screening for fetal aneuploidy. *Obstet Gynecol.* 2016;127(5):e123-e137.

American College of Obstetricians and Gynecologists (ACOG) Committee Opinion. Number No. 640: Cell-free DNA Screening for Fetal Aneuploidy. *Obstet Gynecol.* 2016;126(3):e31-e37.

Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. *Obstet Gynecol.* 2012;119(5):890-901.

Cherry AM, et al. Diagnostic cytogenetic testing following positive noninvasive prenatal screening results: a clinical laboratory practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genetics in Medicine.* 2017;19(8):845-850.

Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position of the American College of Medical Genetics and Genomics. *Genet Med.* 2016; 18:1056-1065.

Hayes, Inc. Clinical Utility Evaluation.

- Cell-free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Chromosomal Copy Number variants. Published November 9, 2017. Annual review Oct 2019. Accessed February 3, 2020.
- Cell-free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Sex Chromosome Aneuploidy. Published October 26, 2017. Annual review Aug 2019. Accessed February 3, 2020.

- Cell-free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Trisomy 21, 18, and 13 in Low-Risk Women. Published October 2017. Annual review Aug 2019.. Accessed February 3, 2020.
- Cell-free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Trisomy 21, 18, and 13 in High-Risk Women. Published February 16, 2018. Annual Review Mar 2019. Accessed February 3, 2020.

National Society of Genetic Counselors (NSGC). Position Statement: Prenatal Cell-Free DNA Screening. April 2018. Available at: <http://www.nsgc.org>. Accessed February 3, 2020.

Palomaki GE, Kloza EM, Lambert-Messerlaian GM, Haddow JE, Neveux LM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. *Genet Med*. 2011; 13:913-920.

Society for Maternal-Fetal Medicine (SMFM) Publications Committee. SMFM Consult series #36. Prenatal aneuploidy screening using cell-free DNA. *Am J Obstet Gynecol*. 2015; 212:711-716.

Society for Maternal-Fetal Medicine (SMFM) Publications Committee. SMFM Consult series #42. The role of ultrasound in women who undergo cell-free DNA screening. *Am J Obstet Gynecol*. 2017;216(3): B2-B7.

State of WI Medicaid Forward Health Portal, Medicaid Topic # 16957 in Lab section. Emerging Molecular Pathology and Diagnostic Genetic Testing. *Fetal Aneuploidy Testing Using Cell-Free Fetal Deoxyribonucleic Acid*. Available at <https://www.forwardhealth.wi.gov/> Accessed February 3, 2020